Piper Jaffray is out with its report today on Watson Pharmaceuticals WPI, reiterating Overweight.
In its report, Piper Jaffray writes, "With multiple high-value generic opportunities (not to mention Prochieve on the brand side), we continue to believe that visibility on double-digit EPS growth for WPI for at least the next 2-3 years is strong. We reiterate our Overweight rating and $78 PT."
Shares of WPI closed Tuesday at $71.98.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in